Search
Octaverine
go.drugbank.com/drugs/DB21449ExperimentalThe usage of the INN stem '-verine' in the name indicates that Octaverine is a spasmolytic with a papaverine-like action. Octaverine has a monoisotopic molecular weight of 397.19 Da.
Vibozilimod
go.drugbank.com/drugs/DB21505ExperimentalThe usage of the INN stem '-imod' in the name indicates that Vibozilimod is a immunomodulator, both stimulant/suppressive and stimulant. Vibozilimod has a monoisotopic molecular weight of 541.23 Da.
Zectivimod
go.drugbank.com/drugs/DB21525ExperimentalThe usage of the INN stem '-imod' in the name indicates that Zectivimod is a immunomodulator, both stimulant/suppressive and stimulant. Zectivimod has a monoisotopic molecular weight of 527.17 Da.
Icanbelimod
go.drugbank.com/drugs/DB21572ExperimentalThe usage of the INN stem '-imod' in the name indicates that Icanbelimod is a immunomodulator, both stimulant/suppressive and stimulant. Icanbelimod has a monoisotopic molecular weight of 409.18 Da.
Uplarafenib
go.drugbank.com/drugs/DB21661ExperimentalThe usage of the INN stem '-rafenib' in the name indicates that Uplarafenib is a Raf (rapidly accelerated fibrosarcoma) kinase inhibitor. Uplarafenib has a monoisotopic molecular weight of 494.12 Da.
Fosrolapitant
go.drugbank.com/drugs/DB21723InvestigationalThe usage of the INN stem '-pitant' in the name indicates that Fosrolapitant is a neurokinin NK1 (substance P) receptor antagonist. Fosrolapitant has a monoisotopic molecular weight of 654.16 Da.
Flezurafenib
go.drugbank.com/drugs/DB21725ExperimentalThe usage of the INN stem '-rafenib' in the name indicates that Flezurafenib is a Raf (rapidly accelerated fibrosarcoma) kinase inhibitor.
Vormatrigine
go.drugbank.com/drugs/DB21731InvestigationalThe usage of the INN stem '-trigine' in the name indicates that Vormatrigine is a sodium channel blocker, signal transduction modulator. Vormatrigine has a monoisotopic molecular weight of 406.09 Da.
Mupadolimab
go.drugbank.com/drugs/DB16488InvestigationalCPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy.
Troxacitabine
go.drugbank.com/drugs/DB04961InvestigationalThere has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.